156 results on '"Lakatos, P.L."'
Search Results
2. PCR225 The Added Value of the Cognition, Dining, Gastrointestinal Problems, Sleep, and Tiredness Bolt-Ons for the EQ-5D-5L in Patients With Coeliac Disease
3. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort
4. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease — An ECCO-EpiCom study
5. Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study
6. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe — An ECCO-EpiCom study
7. P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
8. P727 Change in Crohnʼs disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
9. P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey
10. P694 Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
11. P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohnʼs disease and ulcerative colitis – 54 week data
12. P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database
13. P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort
14. P411 Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
15. P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
16. P309 Impact of rapid access MR on clinical decision making and patient management in Crohnʼs disease in a tertiary referral center
17. P152 Reconsidering the prognostic value of traditional serologic antibodies in Crohnʼs disease – immunoglobulin classes to take the centre stage
18. P145 Measuring access and quality of care indicators in inflammatory bowel disease in a tertiary referral center
19. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
20. ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients
21. NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease
22. Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 caucasian cohorts
23. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?
24. Management of inflammatory bowel diseases in Eastern Europe
25. PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN’S DISEASE
26. ECCO Position statement on the use of biosimilars for inflammatory bowel disease-an update
27. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: Surgical management and special situations
28. The First European Evidence-Based Consensus on Extra-Intestinal Manifestations in Inflammatory Bowel Disease
29. EIGHT YEARS OF DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST FIVE YEARS OF THE FREEDOM EXTENSION
30. AB0314 Awareness and Acceptance of Biosimilars by Rheumatologists in Eleven Eu Countries
31. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
32. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort
33. P557 Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy
34. P321 The one-year efficacy of infliximab does not depend on the timing of biological therapy in ulcerative colitis
35. DOP074 Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis
36. DOP028 Development of red flags for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative
37. P649 Relationship between clinical characteristics and vitamin D receptor polymorphisms in Crohn's disease
38. P344 Short and medium term efficacy of adalimumab in ulcerative colitis – a multicentre, prospective observational study
39. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis
40. The management of iron deficiency in inflammatory bowel disease
41. P321 Vitamin D level doesn't correlate with disease extent and severity in Hungarian patients with inflammatory bowel disease
42. P402 Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy
43. P460 Is it necessary to perform x-ray absorptiometry in young IBD patients to predict the risk of fracture?
44. 183 MANNOSE-BINDING LECTIN DEFICIENCY CONFERS RISK FOR INFECTIONS IN A LARGE HUNGARIAN COHORT OF PATIENTS WITH LIVER CIRRHOSIS
45. P133 - Adherence to therapy and use of complementary and alternative medicine in patients with inflammatory bowel diseases
46. P226 - High incidence of Crohn's disease in Western Hungary between 2002 2006
47. P129 - The impact of concomitant treatment with immuno-modulators and antibiotics on the outcome of C. difficile-associated inflammatory bowel disease exacerbation: an ECCO multi-center retrospective study
48. 8 - Azathioprine/biological therapy does prevent surgery but not reoperation in smokers with Crohn's disease
49. P295 - MBL level and deficiency is not associated with either Crohn's disease or ulcerative colitis, disease phenotype, CRP, serology profile and NOD2/CARD15 genotype in a large Hungarian IBD cohort, but was associated to the lack of TLR4 variants in CD
50. P015 - Pancreatic autoantibodies are associated with reactivity to microbial antibodies penetrating disease behavior perianal disease and extraintestinal manifestations but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.